Drug intelligence / Profile preview

tasronetide

Development stage: Unknown
Lead developer: Find Therapeutics
Modality: Peptides

Overview

Tasronetide is a peptide drug candidate developed by Find Therapeutics. It targets the NRP1/Plexin-A1 receptor complex to promote remyelination, making it a potential treatment for demyelinating diseases such as Multiple Sclerosis. The drug successfully completed a Phase 1 trial in healthy subjects and is undergoing Phase 2-readiness activities, including a Phase 1b PET imaging trial in Multiple Sclerosis patients.

Targets

NRP1 (Neuropilin-1)PLXNA1 (Plexin-A1)Neuropilin-1/Plexin-A1 receptor complex

Beyond the preview

Go deeper on tasronetide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tasronetide.

Explore the full profile